Baker Bros. Advisors LP has filed an amendment to its Schedule 13D, revealing a significant increase in its ownership of Madrigal Pharmaceuticals, Inc. The firm now holds a 9.99% stake in the company, which is notable given the competitive nature of the pharmaceutical industry.

This filing, dated November 6, 2026, indicates that Baker Bros. has acquired a total of 2,330,144 shares of Madrigal Pharmaceuticals, reflecting a more than 1% change in beneficial ownership. The firm has expressed intentions to continue assessing its investment strategy in relation to Madrigal, which could include further acquisitions or discussions with the company's management.

Background

Baker Bros. Advisors LP is a Delaware-based investment firm focused on the life sciences sector. The company has a history of investing in biotechnology and pharmaceutical companies, leveraging its expertise to identify promising investment opportunities. Madrigal Pharmaceuticals, Inc., the subject of this investment, operates within the pharmaceutical preparations industry, specifically focusing on developing innovative therapies for various health conditions.

What the Filing Says

The Schedule 13D/A filing states, "This Amendment No. 5 is being filed to report the acquisition of common stock of Madrigal Pharmaceuticals, Inc. that resulted in a more than 1 percent change in beneficial ownership." Baker Bros. has indicated that it may continue to acquire additional securities based on various factors, including market conditions and the company's business prospects.

Impact

This increase in ownership could have significant implications for both Baker Bros. and Madrigal Pharmaceuticals. For Baker Bros., it solidifies its position as a major stakeholder, potentially influencing the company's strategic decisions. For Madrigal, this investment may enhance its credibility and attract further interest from other investors, as well as increase scrutiny from competitors.

What's Next

The filing does not specify what actions Baker Bros. may take next, but it suggests that the firm is actively monitoring its investment and may engage in further discussions with Madrigal's management regarding future strategies.